What the Business Does
Thermo Fisher Scientific Inc (TMO) operates in the healthcare sector, focusing on diagnostics and research. The company provides a wide range of laboratory instruments, reagents, and consumables that support the life sciences, healthcare, and diagnostics industries. Their products and services are integral to laboratories around the world, which standardize on Thermo Fisher's instruments for efficiency and reliability.
The Buffett-Framework Verdict
Using the Buffett framework, Thermo Fisher's overall score is 40, receiving a grade of C. The market currently values the company at approximately 26 times its earnings, while the return on invested capital (ROIC) stands at just 7.3 percent. This suggests that the market is pricing Thermo Fisher as a premium business, despite its performance metrics indicating otherwise.
Pillar Scores
- Moat: 33
- Durability: 66
- Management: 53
- Valuation: 25
- Financial Health: 35
The company's gross margin is robust at 39.4 percent, indicating strong pricing power and efficiency in operations. However, concerns about valuation and growth persist.
Valuation and Margin of Safety
As of now, Thermo Fisher's stock price is $605. The earnings yield is only 3.48 percent, which is lower than the risk-free Treasury yield. This raises alarms about the stock's valuation, especially given that the earnings per share have been declining at a rate of 2.4 percent annually. With a market cap of approximately $223.7 billion, the company's current valuation seems stretched, particularly when considering the EV to EBIT ratio of 27.2.
The Bull Case
Supporters of Thermo Fisher may point to several strengths:
- Sustainable Cash Flow: Free cash flow constitutes 93.4 percent of reported net income, indicating solid operational performance.
- Solid Operating Margin: With an operating margin of 17.8 percent, the company retains a significant portion of sales as profit.
- Reduced Share Count: Management has reduced the share count by about 1.2 percent annually, returning capital to shareholders rather than diluting ownership.
- Resilience: The business has shown resilience during downturns, with the worst earnings decline contained to 12.4 percent.
These factors suggest that Thermo Fisher has a stable business model, which could support its valuation if market conditions improve.
The Bear Case
On the other hand, several concerns could deter potential investors:
- High Valuation: The primary issue is the high price-to-earnings ratio of 26.4, which may not be justified given the low ROIC and stagnant earnings.
- Heavy Leverage: With net debt at 3.58 times EBITDA, the company faces financial risk, particularly if interest rates rise.
- Stagnant Revenue Growth: Revenues have compounded at a mere 3.2 percent, which does not provide a compelling reason to justify the current stock price.
- Earnings Decline: The ongoing decline in earnings per share raises red flags for long-term investors.
The Bottom Line
Thermo Fisher Scientific Inc presents a mixed investment case in 2026. While the company has strong operational metrics and a resilient business model, the high valuation coupled with declining earnings and heavy debt raise significant concerns. Investors should weigh these factors carefully when considering an investment in TMO.
This is educational, not financial advice. For more details, visit the Buffett verdict for TMO and check the stock page for TMO.